Valuation
- Market cap
- 404,749,000
- Revenue TTM
- $84,280,000
- Net income TTM
- $-171,300,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -203.25%
- Debt to equity
- 13.72
Trading
- Volume
- 1,828,600
- Avg volume
- 1,792,290
- Day's range
- $3.98 – $4.27
- Shares out
- 99,447,000
- Stochastic %K
- 15%
- Beta
- 0.85
- Analysts
- Strong Sell
- Price target
- $24.33
Company profile
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San...
Show more
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 771 9307
- Website
- https://ars-pharma.com
- Address
- 11682 El Camino Real, Suite 300, San Diego, United States
Latest news
No headlines yet.
